On the Path to a Cure for COPD | Johns Hopkins Medicine
2024年10月3日 · Neptune is an organizer of COPD-iNET, an international group of experts with a mission to explore new research and therapies to end COPD. “We need to have all the critical components of the research world talking to each other and coming up with the exciting ideas we can all pursue,” Neptune says. One goal is to get 10 drugs in the pipeline ...
Stephanie Christenson, MD: An "Exciting" New Era in COPD …
4 天之前 · After a pair of historic approvals in 2024, the pulmonology community heads into 2025 with a revamped armamentarium boasting new options for chronic obstructive pulmonary disease (COPD) management, including the first biologic therapy ever approved for the condition with ensifentrine (Ohtuvayre) and dupilumab (Dupixent). 1 “There's so many people that are still suffering,” said Stephanie ...
COPD News Today Home | COPD News Today
2024年9月18日 · FDA approves Dupixent for adults with poorly controlled COPD. The U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) as an add-on maintenance treatment for adults with poorly controlled chronic obstructive pulmonary disease (COPD) and high counts of immune cells called eosinophils.
COPD News - ScienceDaily
3 天之前 · Latest research news on COPD, including chronic bronchitis, chronic obstructive airway disease, chronic obstructive lung disease and emphysema.
New Advances in Managing COPD | TIME
2024年3月18日 · From innovative new lung valves to refinements in the deployment of inhaled therapies and vaccines, the landscape of COPD care and treatment is changing. For people with COPD—and their care...
Sanofi US News
Dupixent is indicated for the approximately 300,000 adults in the US with inadequately controlled COPD and an eosinophilic phenotype; Following recent approvals in the EU and China, the …
A New COPD Treatment is FDA Approved
This article was written by Jonnie Korinko, MSRC, RRT, RRT-ACCS.On June 26, 2024, Verona Pharmaceuticals announced that its new medication, Ensifentrine (Ohtuvayre), was approved …
Dupixent as New Treatment for COPD - HealthCentral
Dupixent is not the only potential new drug for COPD. Itepekimab, a biologic being developed by Sanofi and Regeneron, is now in phase three clinical trials. This drug targets interleukin 33 (IL …
FDA approves new COPD drug developed by firm in Raleigh. First new …
A new COPD drug, developed by Verona Pharma, was approved by the FDA Wednesday. The drug, ensifentrine, is the first new type of maintenance treatment for COPD in over a decade.
GOLD COPD report: 2023 update - The Lancet Respiratory Medicine
On Nov 14, 2022, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) published their 2023 global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (COPD). Highlights from the 2023 report were presented at the 2022 GOLD International COPD conference.